Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Cytodyn Inc (CYDY)

Cytodyn Inc (CYDY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
December 2024 Letter to Shareholders GlobeNewswire - Tue Dec 17, 7:30AM CST

CYDY : 0.1190 (+2.76%)
CytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology GlobeNewswire - Mon Nov 25, 7:30AM CST

CYDY : 0.1190 (+2.76%)
CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial GlobeNewswire - Mon Nov 4, 7:30AM CST

CYDY : 0.1190 (+2.76%)
CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories GlobeNewswire - Wed Oct 30, 7:30AM CDT

CYDY : 0.1190 (+2.76%)
CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development GlobeNewswire - Tue Oct 8, 7:30AM CDT

CYDY : 0.1190 (+2.76%)
CytoDyn Announces Abstract that Highlights Leronlimab’s Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques GlobeNewswire - Mon Oct 7, 10:05AM CDT

CYDY : 0.1190 (+2.76%)
CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial GlobeNewswire - Fri Oct 4, 7:30AM CDT

CYDY : 0.1190 (+2.76%)
CYTODYN ALERT: Bragar Eagel & Squire, P.C. is Investigating CytoDyn, Inc. on Behalf of CytoDyn Stockholders and Encourages Investors to Contact the Firm Business Wire - Thu Aug 11, 2022

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against CytoDyn, Inc. (“CytoDyn” or the “Company”) (OTCMKTS: CYDY) on behalf...

CYDY : 0.1190 (+2.76%)
CYTODYN ALERT: Bragar Eagel & Squire, P.C. is Investigating CytoDyn, Inc. on Behalf of CytoDyn Stockholders and Encourages Investors to Contact the Firm Business Wire - Wed Aug 10, 2022

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against CytoDyn, Inc. (“CytoDyn” or the “Company”) (OTCMKTS: CYDY) on behalf...

CYDY : 0.1190 (+2.76%)
CytoDyn Appoints Cyrus Arman, Ph.D., MBA, as President Globe Newswire - Wed Jul 13, 2022

VANCOUVER, Washington, July 13, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing...

CYDY : 0.1190 (+2.76%)

Barchart Exclusives

Is Rumble Stock a Buy, Sell, or Hold After a $775 Million Investment? Barchart - 1 hour ago
Rumble’s stock has shot up following an investment agreement with a giant crypto firm. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot